cached image

Katherine L.B. Borden, PhD - Publications

Affiliations: 
Dalhousie University, Halifax, Nova Scotia, Canada 
 Mount Sinai School of Medicine, New York, NY 
 Université de Montréal, Montréal, Canada 
Area:
molecular basis of cancer
Website:
https://www.iric.ca/en/research/principal-investigators/katherine-borden/

134 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Osborne MJ, Rahardjo AK, Volpon L, Borden KLB. H, C and N chemical shift assignments of the C-terminal domain of human UDP-Glucuronosyltransferase 2B7 (UGT2B7-C). Biomolecular Nmr Assignments. PMID 33870481 DOI: 10.1007/s12104-021-10024-9  1
2020 Culjkovic-Kraljacic B, Skrabanek L, Revuelta MV, Gasiorek J, Cowling VH, Cerchietti L, Borden KLB. The eukaryotic translation initiation factor eIF4E elevates steady-state mG capping of coding and noncoding transcripts. Proceedings of the National Academy of Sciences of the United States of America. PMID 33055213 DOI: 10.1073/pnas.2002360117  1
2020 Borden KLB, Volpon L. The diversity, plasticity, and adaptability of cap-dependent translation initiation and the associated machinery. Rna Biology. 1-13. PMID 32496897 DOI: 10.1080/15476286.2020.1766179  1
2019 Coutinho de Oliveira L, Volpon L, Rahardjo AK, Osborne MJ, Culjkovic-Kraljacic B, Trahan C, Oeffinger M, Kwok BH, Borden KLB. Structural studies of the eIF4E-VPg complex reveal a direct competition for capped RNA: Implications for translation. Proceedings of the National Academy of Sciences of the United States of America. PMID 31712417 DOI: 10.1073/pnas.1904752116  1
2019 Zahreddine HA, Culjkovic-Kraljacic B, Gasiorek J, Duchaine J, Borden KLB. GLI1-inducible glucuronidation targets a broad spectrum of drugs. Acs Chemical Biology. PMID 30763062 DOI: 10.1021/acschembio.8b01118  1
2019 Volpon L, Osborne MJ, Borden KLB. Biochemical and Structural Insights into the eukaryotic translation initiation factor eIF4E. Current Protein & Peptide Science. PMID 30636602 DOI: 10.2174/1389203720666190110142438  1
2018 Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, ... ... Borden KLB, et al. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene. PMID 30478448 DOI: 10.1038/S41388-018-0567-7  1
2018 Culjkovic-Kraljacic B, Borden KLB. The Impact of Post-transcriptional Control: Better Living Through RNA Regulons. Frontiers in Genetics. 9: 512. PMID 30455716 DOI: 10.3389/fgene.2018.00512  1
2018 Osborne MJ, de Oliveira LC, Volpon L, Zahreddine HA, Borden KLB. Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronsyltransferase Enzymes. Journal of Molecular Biology. PMID 30428301 DOI: 10.1016/j.jmb.2018.11.007  1
2018 Coutinho de Oliveira L, Volpon L, Osborne MJ, Borden KLB. Chemical shift assignment of the viral protein genome-linked (VPg) from potato virus Y. Biomolecular Nmr Assignments. PMID 30242622 DOI: 10.1007/s12104-018-9842-3  1
2018 Ngeow KC, Friedrichsen HJ, Li L, Zeng Z, Andrews S, Volpon L, Brunsdon H, Berridge G, Picaud S, Fischer R, Lisle R, Knapp S, Filippakopoulos P, Knowles H, Steingrímsson E, ... Borden KLB, et al. BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export. Proceedings of the National Academy of Sciences of the United States of America. PMID 30150413 DOI: 10.1073/pnas.1810498115  1
2018 Li L, Friedrichsen HJ, Andrews S, Picaud S, Volpon L, Ngeow K, Berridge G, Fischer R, Borden KLB, Filippakopoulos P, Goding CR. A TFEB nuclear export signal integrates amino acid supply and glucose availability. Nature Communications. 9: 2685. PMID 29992949 DOI: 10.1038/s41467-018-04849-7  1
2018 Osborne MJ, Coutinho de Oliveira L, Volpon L, Borden KLB. Backbone assignment of the apo-form of the human C-terminal domain of UDP-glucuronosyltransferase 1A (UGT1A). Biomolecular Nmr Assignments. PMID 29934866 DOI: 10.1007/s12104-018-9830-7  1
2017 Zahreddine HA, Culjkovic-Kraljacic B, Emond A, Pettersson F, Midura R, Lauer M, Del Rincon S, Cali V, Assouline S, Miller WH, Hascall V, Borden K. The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity. Elife. 6. PMID 29111978 DOI: 10.7554/Elife.29830  1
2017 Volpon L, Culjkovic-Kraljacic B, Sohn HS, Blanchett-Cohen A, Osborne MJ, Borden KL. A biochemical framework for eIF4E-dependent mRNA export and nuclear re-cycling of the export machinery. Rna (New York, N.Y.). PMID 28325843 DOI: 10.1261/rna.060137.116  1
2016 Borden KL. The eukaryotic translation initiation factor eIF4E wears a "cap" for many occasions. Translation (Austin, Tex.). 4: e1220899. PMID 28090419 DOI: 10.1080/21690731.2016.1220899  0.01
2016 Volpon L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, Sun Q, Niesman A, Chook YM, Borden KL. Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E. Proceedings of the National Academy of Sciences of the United States of America. PMID 27114554 DOI: 10.1073/pnas.1524291113  1
2015 Zahreddine HA, Culjkovic-Kraljacic B, Borden KL. Sonic Hedgehog factor Gli1: As good as resistant. Molecular & Cellular Oncology. 2: e961827. PMID 27308395 DOI: 10.4161/23723548.2014.961827  1
2015 Zahreddine HA, Borden KL. Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2207-10. PMID 25810373 DOI: 10.1158/1078-0432.CCR-14-1370  1
2015 Osborne MJ, Borden KL. The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled. Immunological Reviews. 263: 210-23. PMID 25510279 DOI: 10.1111/imr.12240  1
2015 Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH, Borden KL. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. Haematologica. 100: e7-9. PMID 25425688 DOI: 10.3324/Haematol.2014.111245  1
2015 Osborne MJ, Borden KLB. The eukaryotic translation initiation factor eIF4E in the nucleus: Taking the road less traveled Immunological Reviews. 263: 210-223. DOI: 10.1111/imr.12240  1
2014 Culjkovic-Kraljacic B, Zahreddine HA, Borden KL. Inducible drug modification: a new form of resistance. Cell Cycle (Georgetown, Tex.). 13: 2485-6. PMID 25486186 DOI: 10.4161/15384101.2014.946372  1
2014 Landon AL, Muniandy PA, Shetty AC, Lehrmann E, Volpon L, Houng S, Zhang Y, Dai B, Peroutka R, Mazan-Mamczarz K, Steinhardt J, Mahurkar A, Becker KG, Borden KL, Gartenhaus RB. MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL. Nature Communications. 5: 5413. PMID 25403230 DOI: 10.1038/ncomms6413  1
2014 Borden KLB. TIF-90 tips the balance in rRNA synthesis Blood. 124: 467-468. PMID 25061163 DOI: 10.1182/blood-2014-06-578914  1
2014 Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, ... ... Borden KL, et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 511: 90-3. PMID 24870236 DOI: 10.1038/Nature13283  1
2014 Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, ... ... Borden KL, et al. LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase. Cancer Research. 74: 1390-403. PMID 24590809 DOI: 10.1158/0008-5472.Can-13-1275  1
2014 Borden KLB. When will resistance be futile? Cancer Research. 74: 7175-7180. DOI: 10.1158/0008-5472.CAN-14-2607  1
2013 Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, ... ... Borden KL, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discovery. 3: 1002-19. PMID 23955273 DOI: 10.1158/2159-8290.Cd-13-0117  1
2013 Volpon L, Osborne MJ, Culjkovic-Kraljacic B, Borden KLB. EIF4E3, a new actor in mRNA metabolism and tumor suppression Cell Cycle. 12: 1159-1160. PMID 23587918 DOI: 10.4161/Cc.24566  1
2013 Volpon L, Osborne MJ, Zahreddine H, Romeo AA, Borden KL. Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate. Biochemical and Biophysical Research Communications. 434: 614-9. PMID 23583375 DOI: 10.1016/j.bbrc.2013.03.125  1
2013 Culjkovic-Kraljacic B, Borden KLB. Aiding and abetting cancer: MRNA export and the nuclear pore Trends in Cell Biology. 23: 328-335. PMID 23582887 DOI: 10.1016/j.tcb.2013.03.004  1
2013 Zahreddine H, Borden KL. Mechanisms and insights into drug resistance in cancer. Frontiers in Pharmacology. 4: 28. PMID 23504227 DOI: 10.3389/fphar.2013.00028  1
2013 Carroll M, Borden KLB. The oncogene eIF4E: Using biochemical insights to target cancer Journal of Interferon and Cytokine Research. 33: 227-238. PMID 23472659 DOI: 10.1089/jir.2012.0142  1
2013 Hariri F, Arguello M, Volpon L, Culjkovic-Kraljacic B, Nielsen TH, Hiscott J, Mann KK, Borden KL. The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia. Leukemia. 27: 2047-55. PMID 23467026 DOI: 10.1038/Leu.2013.73  1
2013 Osborne MJ, Volpon L, Kornblatt JA, Culjkovic-Kraljacic B, Baguet A, Borden KLB. EIF4E3 acts as a tumor suppressor by utilizing an atypical mode of methyl-7-guanosine cap recognition Proceedings of the National Academy of Sciences of the United States of America. 110: 3877-3882. PMID 23431134 DOI: 10.1073/pnas.1216862110  1
2013 Romeo Y, Moreau J, Zindy PJ, Saba-El-Leil M, Lavoie G, Dandachi F, Baptissart M, Borden KLB, Meloche S, Roux PP. RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth Oncogene. 32: 2917-2926. PMID 22797077 DOI: 10.1038/Onc.2012.312  1
2013 Zahreddine H, Borden KLB. Mechanisms and insights into drug resistance in cancer Frontiers in Pharmacology. 4. DOI: 10.3389/fphar.2013.00028  1
2012 Assouline S, Cocolakis E, Borden KL. The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers. 4: 1161-79. PMID 24213503 DOI: 10.3390/cancers4041161  1
2012 Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, Fang F, Gascoyne RD, Martinez-Climent JA, Glickman JF, Borden K, et al. MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo Cancer Cell. 22: 812-824. PMID 23238016 DOI: 10.1016/J.Ccr.2012.11.003  1
2012 Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden KLB. The Oncogene eIF4E Reprograms the Nuclear Pore Complex to Promote mRNA Export and Oncogenic Transformation Cell Reports. 2: 207-215. PMID 22902403 DOI: 10.1016/j.celrep.2012.07.007  1
2012 Siddiqui N, Tempel W, Nedyalkova L, Volpon L, Wernimont AK, Osborne MJ, Park HW, Borden KLB. Structural insights into the allosteric effects of 4EBP1 on the eukaryotic translation initiation factor eIF4E Journal of Molecular Biology. 415: 781-792. PMID 22178476 DOI: 10.1016/j.jmb.2011.12.002  1
2012 Siddiqui N, Borden KLB. mRNA export and cancer Wiley Interdisciplinary Reviews: Rna. 3: 13-25. PMID 21796793 DOI: 10.1002/wrna.101  1
2012 Assouline S, Cocolakis E, Borden KLB. The development of novel therapies for the treatment of acute myeloid leukemia (AML) Cancers. 4: 1161-1179. DOI: 10.3390/cancers4041161  1
2012 Borden KLB, Culjkovic-Kraljacic B. Promyelocytic leukemia protein Access Science. DOI: 10.1036/1097-8542.Yb120291  1
2011 Borden KLB. Targeting the oncogene eIF4E in cancer: From the bench to clinical trials Clinical and Investigative Medicine. 34: E315-E319. PMID 22129918  1
2011 Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia. 25: 1197-200. PMID 21455212 DOI: 10.1038/leu.2011.57  1
2011 Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Retrouvay H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KL, Benz CC, Miller WH. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2874-84. PMID 21415224 DOI: 10.1158/1078-0432.Ccr-10-2334  1
2011 Déléris P, Trost M, Topisirovic I, Tanguay PL, Borden KL, Thibault P, Meloche S. Activation loop phosphorylation of ERK3/ERK4 by group I p21-activated kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated protein kinase 5 signaling pathway. The Journal of Biological Chemistry. 286: 6470-8. PMID 21177870 DOI: 10.1074/Jbc.M110.181529  1
2010 Culjkovic-Kraljacic B, Borden KLB. Puzzled by PML Science. 330: 1183-1184. PMID 21109655 DOI: 10.1126/science.1199405  1
2010 Borden KLB, Culjkovic-Kraljacic B. Ribavirin as an anti-cancer therapy: Acute myeloid leukemia and beyond? Leukemia and Lymphoma. 51: 1805-1815. PMID 20629523 DOI: 10.3109/10428194.2010.496506  1
2010 Volpon L, Osborne MJ, Capul AA, de la Torre JC, Borden KL. Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E. Proceedings of the National Academy of Sciences of the United States of America. 107: 5441-6. PMID 20212144 DOI: 10.1073/Pnas.0909877107  1
2010 García CC, Topisirovic I, Djavani M, Borden KLB, Damonte EB, Salvato MS. An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein Biochemical and Biophysical Research Communications. 393: 625-630. PMID 20152808 DOI: 10.1016/j.bbrc.2010.02.040  1
2010 Pettersson F, Dobocan MC, Retrouvay H, Culjkovic B, Amri A, Gaboury L, Borden KLB, Miller WH. Abstract 3165: Anti-tumor activity of the eIF4E-targeted drug ribavirin in breast cancer cells Cancer Research. 70: 3165-3165. DOI: 10.1158/1538-7445.Am10-3165  1
2009 Culjkovic B, Borden KL. Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer. Journal of Oncology. 2009: 981679. PMID 20049173 DOI: 10.1155/2009/981679  1
2009 Rolef Ben-Shahar T, Castillo AG, Osborne MJ, Borden KL, Kornblatt J, Verreault A. Two fundamentally distinct PCNA interaction peptides contribute to chromatin assembly factor 1 function. Molecular and Cellular Biology. 29: 6353-65. PMID 19822659 DOI: 10.1128/Mcb.01051-09  1
2009 Topisirovic I, Gutierrez GJ, Chen M, Appella E, Borden KL, Ronai ZA. Control of p53 multimerization by Ubc13 is JNK-regulated. Proceedings of the National Academy of Sciences of the United States of America. 106: 12676-81. PMID 19651615 DOI: 10.1073/Pnas.0900596106  1
2009 Ploski JE, Topisirovic I, Park KW, Borden KL, Radu A. A mechanism of nucleocytoplasmic trafficking for the homeodomain protein PRH. Molecular and Cellular Biochemistry. 332: 173-81. PMID 19588232 DOI: 10.1007/S11010-009-0188-0  1
2009 Borden KLB. Tissue targeting in cancer: eIF4E's tale Clinical Cancer Research. 15: 4254-4255. PMID 19509132 DOI: 10.1158/1078-0432.CCR-09-0552  1
2009 Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH, Borden KL. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 114: 257-60. PMID 19433856 DOI: 10.1182/Blood-2009-02-205153  1
2009 Topisirovic I, Siddiqui N, Borden KLB. The eukaryotic translation initiation factor 4E (eIF4E) and HuR RNA operons collaboratively regulate the expression of survival and proliferative genes Cell Cycle. 8: 960-961. PMID 19287207 DOI: 10.4161/Cc.8.7.8093  1
2009 Borden KLB, Culjkovic B. Perspectives in PML: A unifying framework for PML function Frontiers in Bioscience. 14: 497-509. PMID 19273081 DOI: 10.2741/3258  1
2009 Topisirovic I, Siddiqui N, Lapointe VL, Trost M, Thibault P, Bangeranye C, P?ol-Roma S, Borden KLB. Molecular dissection of the eukaryotic initiation factor 4E (eIF4E) export-competent RNP Embo Journal. 28: 1087-1098. PMID 19262567 DOI: 10.1038/Emboj.2009.53  1
2009 Topisirovic I, Siddiqui N, Orolicki S, Skrabanek LA, Tremblay M, Hoang T, Borden KLB. Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer Molecular and Cellular Biology. 29: 1152-1162. PMID 19114552 DOI: 10.1128/Mcb.01532-08  1
2009 Borden KL, Culjkovic B. Understanding and targeting the eukaryotic translation initiation factor eif4E in head and neck cancer Journal of Oncology. DOI: 10.1155/2009/981679  1
2008 Volpon L, Osborne MJ, Borden KLB. NMR assignment of the arenaviral protein Z from Lassa fever virus Biomolecular Nmr Assignments. 2: 81-84. PMID 18958179 DOI: 10.1007/s12104-008-9090-z  1
2008 Tan K, Culjkovic B, Amri A, Borden KLB. Ribavirin targets eIF4E dependent Akt survival signaling Biochemical and Biophysical Research Communications. 375: 341-345. PMID 18706892 DOI: 10.1016/j.bbrc.2008.07.163  1
2008 Ebralidze AK, Guibal FC, Steidl U, Zhang P, Lee S, Bartholdy B, Jorda MA, Petkova V, Rosenbauer F, Huang G, Dayaram T, Klupp J, O'Brien KB, Will B, Hoogenkamp M, ... Borden KLB, et al. PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element Genes and Development. 22: 2085-2092. PMID 18676813 DOI: 10.1101/gad.1654808  1
2008 Borden KLB. Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: Can we fit the pieces together using an RNA regulon? Biochimica Et Biophysica Acta - Molecular Cell Research. 1783: 2145-2154. PMID 18616965 DOI: 10.1016/j.bbamcr.2008.06.005  1
2008 Culjkovic B, Tan K, Orolicki S, Amri A, Meloche S, Borden KLB. The eIF4E RNA regulon promotes the Akt signaling pathway Journal of Cell Biology. 181: 51-63. PMID 18391071 DOI: 10.1083/Jcb.200707018  1
2008 Djavani M, Topisirovic I, Zapata JC, Sadowska M, Yang Y, Rodas J, Lukashevich IS, Bogue CW, Pauza CD, Borden KLB, Salvato MS. The Proline-Rich Homeodomain (PRH/HEX) protein is down-regulated in liver during infection with lymphocytic choriomeningitis virus (Journal of Virology (2005) 79, 4, (2461-2473)) Journal of Virology. 82: 8954. DOI: 10.1128/JVI.01304-08  1
2007 Peng H, Gibson LC, Capili AD, Borden KL, Osborne MJ, Harper SL, Speicher DW, Zhao K, Marmorstein R, Rock TA, Rauscher FJ. The structurally disordered KRAB repression domain is incorporated into a protease resistant core upon binding to KAP-1-RBCC domain. Journal of Molecular Biology. 370: 269-89. PMID 17512541 DOI: 10.1016/j.jmb.2007.03.047  1
2007 Culjkovic B, Topisirovic I, Borden KLB. Controlling gene expression through RNA regulons: The role of the eukaryotic translation initiation factor eIF4E Cell Cycle. 6: 65-69. PMID 17245113 DOI: 10.4161/Cc.6.1.3688  1
2007 Poyurovsky MV, Priest C, Kentsis A, Borden KLB, Pan ZQ, Pavletich N, Prives C. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity Embo Journal. 26: 90-101. PMID 17170710 DOI: 10.1038/Sj.Emboj.7601465  1
2006 Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KLB. eIF4E is a central node of an RNA regulon that governs cellular proliferation Journal of Cell Biology. 175: 415-426. PMID 17074885 DOI: 10.1083/Jcb.200607020  1
2006 Volpon L, Osborne MJ, Topisirovic I, Siddiqui N, Borden KLB. Cap-free structure of eIF4E suggests a basis for conformational regulation by its ligands Embo Journal. 25: 5138-5149. PMID 17036047 DOI: 10.1038/sj.emboj.7601380  1
2006 Laine A, Topisirovic I, Zhai D, Reed JC, Borden KLB, Ronai Z. Regulation of p53 localization and activity by Ubc13 Molecular and Cellular Biology. 26: 8901-8913. PMID 17000756 DOI: 10.1128/Mcb.01156-06  1
2006 Volpon L, Osborne MJ, Borden KBL. NMR assignment of human eukaryotic translation initiation factor 4E (eIF4E) in its cap-free form [63] Journal of Biomolecular Nmr. 36: 65. PMID 16871426 DOI: 10.1007/s10858-006-9051-8  1
2006 García CC, Djavani M, Topisirovic I, Borden KLB, Salvato MS, Damonte EB. Arenavirus Z protein as an antiviral target: Virus inactivation and protein oligomerization by zinc finger-reactive compounds Journal of General Virology. 87: 1217-1228. PMID 16603524 DOI: 10.1099/vir.0.81667-0  1
2005 Kentsis A, Volpon L, Topisirovic I, Soll CE, Culjkovic B, Shao L, Borden KLB. Further evidence that ribavirin interacts with eIF4E Rna. 11: 1762-1766. PMID 16251386 DOI: 10.1261/Rna.2238705  1
2005 Topisirovic I, Borden KLB. Homeodomain proteins and eukaryotic translation initiation factor 4E (elF4E): An unexpected relationship Histology and Histopathology. 20: 1275-1284. PMID 16136508 DOI: 10.14670/Hh-20.1275  1
2005 Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KLB. eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3′UTR Journal of Cell Biology. 169: 245-256. PMID 15837800 DOI: 10.1083/Jcb.200501019  1
2005 Djavani M, Topisirovic I, Zapata JC, Sadowska M, Yang Y, Rodas J, Lukashevich IS, Bogue CW, Pauza CD, Borden KL, Salvato MS. The proline-rich homeodomain (PRH/HEX) protein is down-regulated in liver during infection with lymphocytic choriomeningitis virus. Journal of Virology. 79: 2461-73. PMID 15681447 DOI: 10.1128/Jvi.79.4.2461-2473.2005  1
2005 Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Molecular and Cellular Biology. 25: 1100-12. PMID 15657436 DOI: 10.1128/Mcb.25.3.1100-1112.2005  1
2004 Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KLB. Ribavirin suppresses elF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap Proceedings of the National Academy of Sciences of the United States of America. 101: 18105-18110. PMID 15601771 DOI: 10.1073/Pnas.0406927102  1
2004 Topisirovic I, Ruiz-Gutierrez M, Borden KLB. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities Cancer Research. 64: 8639-8642. PMID 15574771 DOI: 10.1158/0008-5472.Can-04-2677  1
2004 Capili AD, Edghill EL, Wu K, Borden KLB. Structure of the C-terminal RING finger from a RING-IBR-RING/TRIAD motif reveals a novel zinc-binding domain distinct from a RING Journal of Molecular Biology. 340: 1117-1129. PMID 15236971 DOI: 10.1016/J.Jmb.2004.05.035  1
2004 Kentsis A, Borden KLB. Physical mechanisms and biological significance of supramolecular protein self-assembly Current Protein and Peptide Science. 5: 125-134. PMID 15078223 DOI: 10.2174/1389203043486856  1
2004 Borden KLB, Freemont PS. Introduction to supermolecular machines and assemblies Current Protein and Peptide Science. 5: xxx.  1
2003 Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, Borden KL. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Molecular and Cellular Biology. 23: 8992-9002. PMID 14645512 DOI: 10.1128/Mcb.23.24.8992-9002.2003  1
2003 Seker H, Rubbi C, Linke SP, Bowman ED, Garfield S, Hansen L, Borden KL, Milner J, Harris CC. UV-C-induced DNA damage leads to p53-dependent nuclear trafficking of PML. Oncogene. 22: 1620-8. PMID 12642865 DOI: 10.1038/Sj.Onc.1206140  1
2003 Topisirovic I, Culjkovic B, Cohen N, Perez JM, Skrabanek L, Borden KL. The proline-rich homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth. The Embo Journal. 22: 689-703. PMID 12554669 DOI: 10.1093/Emboj/Cdg069  1
2002 Kentsis A, Gordon RE, Borden KLB. Control of biochemical reactions through supramolecular RING domain self-assembly Proceedings of the National Academy of Sciences of the United States of America. 99: 15404-15409. PMID 12438698 DOI: 10.1073/Pnas.202608799  1
2002 Strudwick S, Borden KL. Finding a role for PML in APL pathogenesis: a critical assessment of potential PML activities. Leukemia. 16: 1906-17. PMID 12357342 DOI: 10.1038/sj.leu.2402724  1
2002 Topisirovic I, Capili AD, Borden KL. Gamma interferon and cadmium treatments modulate eukaryotic initiation factor 4E-dependent mRNA transport of cyclin D1 in a PML-dependent manner. Molecular and Cellular Biology. 22: 6183-98. PMID 12167712 DOI: 10.1128/Mcb.22.17.6183-6198.2002  1
2002 Borden KL. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Molecular and Cellular Biology. 22: 5259-69. PMID 12101223 DOI: 10.1128/Mcb.22.15.5259-5269.2002  1
2002 Strudwick S, Borden KL. The emerging roles of translation factor eIF4E in the nucleus. Differentiation; Research in Biological Diversity. 70: 10-22. PMID 11963652 DOI: 10.1046/J.1432-0436.2002.700102.X  1
2002 Kentsis A, Gordon RE, Borden KLB. Self-assembly properties of a model RING domain Proceedings of the National Academy of Sciences of the United States of America. 99: 667-672. PMID 11792829 DOI: 10.1073/Pnas.012317299  1
2001 Kentsis A, Dwyer EC, Perez JM, Sharma M, Chen A, Pan ZQ, Borden KLB. The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E Journal of Molecular Biology. 312: 609-623. PMID 11575918 DOI: 10.1006/Jmbi.2001.5003  1
2001 Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KLB. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA Embo Journal. 20: 4547-4559. PMID 11500381 DOI: 10.1093/Emboj/20.16.4547  1
2001 Djavani M, Rodas J, Lukashevich IS, Horejsh D, Pandolfi PP, Borden KL, Salvato MS. Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. Journal of Virology. 75: 6204-8. PMID 11390623 DOI: 10.1128/Jvi.75.13.6204-6208.2001  1
2001 Capili AD, Schultz DC, RauscherIII FJ, Borden KL. Solution structure of the PHD domain from the KAP-1 corepressor: structural determinants for PHD, RING and LIM zinc-binding domains. The Embo Journal. 20: 165-77. PMID 11226167 DOI: 10.1093/Emboj/20.1.165  1
2000 Kentsis A, Borden KLB. Construction of Macromolecular Assemblages in Eukaryotic Processes and their Role in Human Disease: Linking RINGs Together Current Protein and Peptide Science. 1: 49-73. PMID 12369920  1
2000 Topcu Z, Borden KL. The yeast two-hybrid system and its pharmaceutical significance. Pharmaceutical Research. 17: 1049-55. PMID 11087035 DOI: 10.1023/A:1026493310144  1
2000 Melnick A, Ahmad KF, Arai S, Polinger A, Ball H, Borden KL, Carlile GW, Prive GG, Licht JD. In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions. Molecular and Cellular Biology. 20: 6550-67. PMID 10938130 DOI: 10.1128/Mcb.20.17.6550-6567.2000  1
2000 Lai HK, Borden KL. The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA. Oncogene. 19: 1623-34. PMID 10763819 DOI: 10.1038/Sj.Onc.1203473  1
2000 Campbell Dwyer EJ, Lai H, MacDonald RC, Salvato MS, Borden KL. The lymphocytic choriomeningitis virus RING protein Z associates with eukaryotic initiation factor 4E and selectively represses translation in a RING-dependent manner. Journal of Virology. 74: 3293-300. PMID 10708446 DOI: 10.1128/Jvi.74.7.3293-3300.2000  1
2000 Borden KL. RING domains: master builders of molecular scaffolds? Journal of Molecular Biology. 295: 1103-12. PMID 10653689 DOI: 10.1006/Jmbi.1999.3429  1
2000 Kentsis A, Sharma M, Ferez JM, Borden KLB. Reconstructing the pml nuclear body: pml binds eif4e and lowers its affinity for 5' cap of mrna Blood. 96: 91a.  1
1999 Topcu Z, Mack DL, Hromas RA, Borden KL. The promyelocytic leukemia protein PML interacts with the proline-rich homeodomain protein PRH: a RING may link hematopoiesis and growth control. Oncogene. 18: 7091-100. PMID 10597310 DOI: 10.1038/Sj.Onc.1203201  1
1998 Borden KL. RING fingers and B-boxes: zinc-binding protein-protein interaction domains. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 76: 351-8. PMID 9923704 DOI: 10.1139/Bcb-76-2-3-351  1
1998 Carlile GW, Tatton WG, Borden KL. Demonstration of a RNA-dependent nuclear interaction between the promyelocytic leukaemia protein and glyceraldehyde-3-phosphate dehydrogenase. The Biochemical Journal. 335: 691-6. PMID 9794812 DOI: 10.1042/Bj3350691  1
1998 Borden KL. Structure/function in neuroprotection and apoptosis. Annals of Neurology. 44: S65-71. PMID 9749576 DOI: 10.1002/Ana.410440711  1
1998 Cao T, Duprez E, Borden KL, Freemont PS, Etkin LD. Ret finger protein is a normal component of PML nuclear bodies and interacts directly with PML. Journal of Cell Science. 111: 1319-29. PMID 9570750  1
1998 Borden KL, Campbelldwyer EJ, Carlile GW, Djavani M, Salvato MS. Two RING finger proteins, the oncoprotein PML and the arenavirus Z protein, colocalize with the nuclear fraction of the ribosomal P proteins. Journal of Virology. 72: 3819-26. PMID 9557665 DOI: 10.1128/Jvi.72.5.3819-3826.1998  1
1998 Borden KL, Campbell Dwyer EJ, Salvato MS. An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. Journal of Virology. 72: 758-66. PMID 9420283 DOI: 10.1128/Jvi.72.1.758-766.1998  1
1997 Borden KL, CampbellDwyer EJ, Salvato MS. The promyelocytic leukemia protein PML has a pro-apoptotic activity mediated through its RING domain. Febs Letters. 418: 30-4. PMID 9414089 DOI: 10.1016/S0014-5793(97)01344-6  1
1997 Boddy MN, Duprez E, Borden KL, Freemont PS. Surface residue mutations of the PML RING finger domain alter the formation of nuclear matrix-associated PML bodies. Journal of Cell Science. 110: 2197-205. PMID 9378769  1
1997 Cao T, Borden KL, Freemont PS, Etkin LD. Involvement of the rfp tripartite motif in protein-protein interactions and subcellular distribution. Journal of Cell Science. 110: 1563-71. PMID 9247190  1
1996 Borden KL, Freemont PS. The RING finger domain: a recent example of a sequence-structure family. Current Opinion in Structural Biology. 6: 395-401. PMID 8804826 DOI: 10.1016/S0959-440X(96)80060-1  1
1996 Saurin AJ, Borden KL, Boddy MN, Freemont PS. Does this have a familiar RING? Trends in Biochemical Sciences. 21: 208-14. PMID 8744354 DOI: 10.1016/S0968-0004(96)80017-X  1
1996 Borden KL, Lally JM, Martin SR, O'Reilly NJ, Solomon E, Freemont PS. In vivo and in vitro characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia protooncoprotein PML. Proceedings of the National Academy of Sciences of the United States of America. 93: 1601-6. PMID 8643677 DOI: 10.1073/Pnas.93.4.1601  1
1995 Borden KLB, Lally JM, Martin SR, O'Reilly NJ, Etkin LD, Freemont PS. Novel topology of a zinc-binding domain from a protein involved in regulating early Xenopus development Embo Journal. 14: 5947-5956. PMID 8846787  1
1995 Borden KL, Boddy MN, Lally J, O'Reilly NJ, Martin S, Howe K, Solomon E, Freemont PS. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. The Embo Journal. 14: 1532-41. PMID 7729428 DOI: 10.1002/J.1460-2075.1995.Tb07139.X  1
1994 Boddy MN, Freemont PS, Borden KL. The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends in Biochemical Sciences. 19: 198-9. PMID 8048160 DOI: 10.1016/0968-0004(94)90020-5  1
1994 Borden KLB. Two mutant binding sites of the activating transcription factor region within the E2A promoter of adenovirus exist in a novel conformation Bba - Gene Structure and Expression. 1219: 505-514. PMID 7918649 DOI: 10.1016/0167-4781(94)90078-7  1
1993 Borden KLB. The activating transcription factor region within the E2A promoter exists in a novel conformation Biochemistry. 32: 6506-6514. PMID 8329380  1
1993 Borden KLB, Martin SR, O'Reilly NJ, Lally JM, Reddy BA, Etkin LD, Freemont PS. Characterisation of a novel cysteine/histidine-rich metal binding domain from Xenopus nuclear factor XNF7 Febs Letters. 335: 255-260. PMID 8253208 DOI: 10.1016/0014-5793(93)80741-C  1
1993 Lovering R, Hanson IM, Borden KLB, Martin S, O'Reilly NJ, Evan GI, Rahman D, Pappin DJC, Trowsdale J, Freemont PS. Identification and preliminary characterization of a protein motif related to the zinc finger Proceedings of the National Academy of Sciences of the United States of America. 90: 2112-2116. PMID 7681583 DOI: 10.1073/Pnas.90.6.2112  1
1992 Borden KLB, Bauer CJ, Frenkiel TA, Beckmann P, Lane AN. Sequence-specific NMR assignments of the trp repressor from Escherichia coli using three-dimensional 15N/1H heteronuclear techniques European Journal of Biochemistry. 204: 137-146. PMID 1740124  1
1992 Borden KLB, Jenkins TC, Skelly JV, Brown T, Lane AN. Conformational properties of the G·G mismatch in d(CGCGAATTGGCG)2 determined by NMR Biochemistry. 31: 5411-5422. PMID 1606167 DOI: 10.1021/Bi00138A024  1
1991 Borden KLB, Beckmann P, Lane AN. Determination of the orientations of tryptophan analogues bound to the trp repressor and the relationship to activation European Journal of Biochemistry. 202: 459-470. PMID 1761046 DOI: 10.1111/j.1432-1033.1991.tb16395.x  1
1990 Borden KL, Richards FM. Folding of the reduced form of the thioredoxin from bacteriophage T4. Biochemistry. 29: 8207-10. PMID 2252882 DOI: 10.1021/Bi00488A002  1
1990 Borden KL, Richards FM. Folding kinetics of phage T4 thioredoxin. Biochemistry. 29: 3071-7. PMID 2186806 DOI: 10.1021/Bi00464A025  1
Show low-probability matches.